Daily Washington Insider
  • Business
  • World
  • Science
  • Investing

Daily Washington Insider

  • Business
  • World
  • Science
  • Investing
Investing

Cardiex: Biomarker Technologies, Digital Solutions to Address the World’s Largest Health Disorders

by admin April 20, 2024
April 20, 2024
Cardiex: Biomarker Technologies, Digital Solutions to Address the World’s Largest Health Disorders

Cardiex Limited (ASX:CDX) leverages its proprietary SphygmoCor® technology to develop and market vascular biomarker technologies and digital solutions focused on the world’s largest health disorders. SphygmoCor®, the company’s groundbreaking technology, has set the benchmark for noninvasive measurement of central aortic pressures and related arterial health characteristics, collectively referred to as vascular biomarkers.

The unique physiologic insights from the company’s devices provide clinically relevant information that helps guide treatment decisions and offer profound benefits for all members of the healthcare community:

For Healthcare Providers: Enable physicians to make more informed treatment decisions based on clinically relevant vascular health data.

For Patients: Give patients the tools to make better decisions about their own health.

For Pharmaceutical Companies: Generate reliable, real-world, clinically relevant data to accelerate drug development and commercialization.

Cardiex’s goal is to establish a holistic ecosystem that promotes cardiovascular well-being and empowers users to proactively manage their health as an integral part of individuals’ health routines, contributing to a paradigm shift in preventive cardiovascular care.

The company’s first-mover advantage and exclusive technology FDA-cleared for noninvasive measurement of central pulse pressures and vascular biomarkers across all adult demographics grant it a distinctive market position. CDX recently secured AU$14 million in funding, which is enough to steer the company towards profitability.

Company Highlights

The company’s offerings encompass FDA-cleared medical and home health devices alongside digital solutions tailored for managing health and wellness, delivering unique physiologic insights that inform clinical treatment decisions.The company’s groundbreaking technology – named SphygmoCor® – set the benchmark for measuring central aortic pressures and related arterial health characteristics, collectively referred to as vascular biomarkers.These biomarkers, extensively researched and detailed in numerous peer-reviewed journals, assess cardiovascular risk and guide disease management by predicting organ damage (such as the heart, brain, and kidneys) and outcomes (including heart failure, ischemic heart disease, and stroke), significantly influencing disease prognosis and clinical treatment.CDX received five FDA clearances from 2002 to 2023, the most recent for the CONNEQT Pulse, a world-first connected vascular biometric monitor. The CONNEQT Pulse targets new and significant healthcare channels and transitions the company towards a recurring revenue model based on monthly subscription fees.CDX’s technology is uniquely FDA-cleared for noninvasive measurement of central pulse pressures and vascular biomarkers across all adult demographics – thereby granting it a distinctive competitive market position. With a significant funding round recently secured, CDX is poised for profitability ahead.

This Cardiex profile is part of a paid investor education campaign.*

Click here to connect with Cardiex Limited (ASX:CDX) to receive an Investor Presentation

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Volkswagen workers in Tennessee vote to join UAW in historic win for union
next post
Copper Price Update: Q1 2024 in Review

You may also like

Energy Fuels Announces Q1-2024 Results, Including Continued Net...

May 4, 2024

Lead Price Forecast: Top Trends for Lead in...

January 11, 2025

Altech – Agreement to Secure EUR2.5M in Funding

March 25, 2025

Advisory Board Expansion

May 16, 2024

Additional High Priority Antimony Targets Identified over 10km...

December 12, 2024

Spearmint Significantly Increases Acreage on the Sisson North...

April 14, 2025

Appia Rare Earths and Uranium Corp. to Present...

May 17, 2024

Breaking the Cycle: Can Gold Outshine Historical Trends...

September 4, 2024

Turkey Eyes Chinese Partnership to Develop Rare Earths...

September 4, 2024

Forward Water Technologies Completes Non-Brokered Private Placement of...

May 25, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular

    • 1

      Hong Kong plans to install thousands of surveillance cameras. Critics say it’s...

    • 2

      UN experts urge Thailand not to deport dozens of Uyghurs to China where they face ‘real risk of torture’

    • 3

      China executes man who plowed car into crowds in deadliest attack in a decade

    • 4

      Trump has assembled a team of China hawks. How will Beijing respond?

    • 5

      How Calvin Klein and Tommy Hilfiger got caught in Trump’s trade war with China

    Categories

    • Business (1,300)
    • Investing (3,418)
    • Science (605)
    • World (3,677)
    Footer Logo

    Disclaimer: dailywashingtoninsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 dailywashingtoninsider.com | All Rights Reserved